AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37268971 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tinnitus relieving sound (MTRS)
Number of subjects: 68
Study 37268971 — intervention group
Group type: COMPARATOR
Intervention: Unmodified music (UM)
Number of subjects: 68
Study 37269077 — intervention group
Group type: EXPERIMENTAL
Intervention: Good effort on cognitive tests (defined as not exhibiting poor effort)
Number of subjects: 237
Study 37269077 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor effort on one cognitive test
Number of subjects: 237
Study 37269077 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor effort on two cognitive tests
Number of subjects: 237
Study 37269077 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cognitive testing effort
Number of subjects: 237
Study 37269076 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3739937 (GSK'937) - single doses of 10-800 mg
Number of subjects: 91
Study 37269076 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3739937 (GSK'937) - multiple doses of 25-100 mg once daily or 500 mg once weekly
Number of subjects: 91
Study 37269076 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3739937 (GSK'937) - bioavailability as a tablet versus powder-in-bottle
Number of subjects: 91
Study 37269076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 37269192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (176.4±63.5 min/week)
Number of subjects: 144
Study 37269192 — intervention group
Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 144
Study 37269192 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 144
Study 37269282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and thoracic transcutaneous spinal cord stimulation (scTS)
Number of subjects: 7
Study 37269344 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828) at a maximum tolerated dose of 60 mg for D1q3w and 45 mg for D1D8q4w
Number of subjects: 54
Study 37269344 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Number of subjects: 54
Study 37269841 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium-177 PSMA-targeted radioligand therapy
Number of subjects: 831
Study 37269841 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 831
Study 37269870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangibotide 0.3 mg/kg per h (low-dose group)
Number of subjects: 355
Study 37269870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangibotide 1.0 mg/kg per h (high-dose group)
Number of subjects: 355
Study 37269870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 37269870 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (placebo, low-dose, high-dose)
Number of subjects: 355
Study 37269872 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe-assisted colonoscopy (GI Genius 2.0.2; Medtronic)
Number of subjects: 2015
Study 37269872 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 2015
Study 37269883 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification (presence of gamification with low budget)
Number of subjects: 1228
Study 37269883 — intervention group
Group type: COMPARATOR
Intervention: No gamification (absence of gamification with low budget)
Number of subjects: 1228
Study 37269883 — intervention group
Group type: COMPARATOR
Intervention: Budget amount ($50 vs. $30)
Number of subjects: 1228
Study 37269904 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-programmed cell death protein 1 ± anti-cytotoxic T-lymphocyte-associated protein 4
Number of subjects: 116
Study 37269909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose blueberry powder (2.5%)
Number of subjects: 0
Study 37269909 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose blueberry powder (5%)
Number of subjects: 0
Study 37269909 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 37269941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 0.5 mg/kg once daily for 14 days
Number of subjects: 73
Study 37269941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 1 mg/kg once daily for 7 days
Number of subjects: 73
Study 37269941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 1 mg/kg twice daily for 3.5 days
Number of subjects: 73
Study 37269941 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 73
Study 37270027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF)
Number of subjects: 1989
Study 37270027 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding with at least 1 daily meal of Cows' Milk Formula (CMF)
Number of subjects: 1989
Study 37270027 — intervention group
Group type: COMPARATOR
Intervention: Cows' Milk Formula (CMF) only
Number of subjects: 1989
Study 37270188 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-movement desensitisation and reprocessing therapy (EMDR) plus standard neuropsychiatric care (NPC)
Number of subjects: 50
Study 37270188 — intervention group
Group type: COMPARATOR
Intervention: Standard neuropsychiatric care (NPC)
Number of subjects: 50
Study 37270190 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy delivered by psychologists
Number of subjects: 573
Study 37270190 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist responsiveness to client characteristics and preferences
Number of subjects: 573
Study 37270195 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week pulmonary rehabilitation (PR) programme in primary care, supervised by a physiotherapist
Number of subjects: 134
Study 37270195 — intervention group
Group type: COMPARATOR
Intervention: No pulmonary rehabilitation (control group)
Number of subjects: 134
Study 37270195 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week pulmonary rehabilitation (PR) programme
Number of subjects: 134
Study 37270194 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP)
Number of subjects: 90
Study 37270194 — intervention group
Group type: COMPARATOR
Intervention: Standard Targeted Temperature Management
Number of subjects: 90
Study 37270201 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 15480
Study 37270201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15480
Study 37270201 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine data (Aspirin)
Number of subjects: 15480
Study 37270201 — intervention group
Group type: COMPARATOR
Intervention: Routine data (Placebo)
Number of subjects: 15480
Study 37270289 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d for 48 weeks
Number of subjects: 25
Study 37270291 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples collected from women in Switzerland
Number of subjects: 308
Study 37270291 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples collected from women in South Africa
Number of subjects: 308
Study 37270291 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples collected from women in Tanzania
Number of subjects: 308
Study 37270471 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM)
Number of subjects: 33
Study 37270471 — intervention group
Group type: COMPARATOR
Intervention: Myofascial release therapy (MRT)
Number of subjects: 33
Study 37270517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg twice daily for 8 weeks
Number of subjects: 60
Study 37270517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37270692 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 98
Study 37270691 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFOX (6 cycles over 12 weeks)
Number of subjects: 1194
Study 37270691 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant 5FUCRT (28 fractions over 5.5 weeks)
Number of subjects: 1194
Study 37270698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib, 500 mg once daily
Number of subjects: 313
Study 37270762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) therapy
Number of subjects: 0
Study 37270762 — intervention group
Group type: COMPARATOR
Intervention: Conventional uninformed parametric models
Number of subjects: 0
Study 37270762 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Bayesian survival models
Number of subjects: 0
Study 37270762 — intervention group
Group type: COMPARATOR
Intervention: Uninformed log-normal model
Number of subjects: 0
Study 37270840 — intervention group
Group type: EXPERIMENTAL
Intervention: Melancholic depression (MD) patients
Number of subjects: 227
Study 37270840 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmelancholic depression (NMD) patients
Number of subjects: 227
Study 37270840 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 227
Study 37271020 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training Rehabilitation (ETR)
Number of subjects: 60
Study 37271020 — intervention group
Group type: COMPARATOR
Intervention: Standard Physiotherapy (SP)
Number of subjects: 60
Study 37271067 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD) for 2 weeks preoperatively
Number of subjects: 53
Study 37271067 — intervention group
Group type: COMPARATOR
Intervention: Standard procedural fasting
Number of subjects: 53
Study 37271356 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive PCI plus optimal medical therapy (OMT)
Number of subjects: 1608
Study 37271356 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 1608
Study 37271412 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3600 mg per day
Number of subjects: 60
Study 37271412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37271416 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-mg ferrous sulfate
Number of subjects: 480
Study 37271416 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-mg ferrous bisglycinate
Number of subjects: 480
Study 37271416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 37271416 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of iron groups
Number of subjects: 480
Study 37271416 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 480
Study 37271418 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophy in the medial temporal lobe and subregions of the motor and prefrontal cortex
Number of subjects: 283
Study 37271418 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread reduced white matter integrity
Number of subjects: 283
Study 37271418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall associations
Number of subjects: 283
Study 37271576 — intervention group
Group type: EXPERIMENTAL
Intervention: Food tracking adherence of 28.5% of intervention days
Number of subjects: 153
Study 37271576 — intervention group
Group type: EXPERIMENTAL
Intervention: Food tracking adherence of 39.4% of intervention days
Number of subjects: 153
Study 37271576 — intervention group
Group type: EXPERIMENTAL
Intervention: Food tracking adherence of 67.1% of intervention days
Number of subjects: 153
Study 37271576 — intervention group
Group type: EXPERIMENTAL
Intervention: Food tracking trajectories identified through time series clustering
Number of subjects: 153
Study 37271593 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 30
Study 37271593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 37271594 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 1346
Study 37271594 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipidic burden
Number of subjects: 1346
Study 37271594 — intervention group
Group type: COMPARATOR
Intervention: White patients
Number of subjects: 1346
Study 37271703 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19)
Number of subjects: 256
Study 37271703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 37271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth dose of NVX-CoV2373 (5 µg rS protein + 50 µg Matrix-M adjuvant)
Number of subjects: 1283
Study 37271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of NVX-CoV2373
Number of subjects: 1283
Study 37271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth dose of NVX-CoV2373
Number of subjects: 1283
Study 37271706 — intervention group
Group type: COMPARATOR
Intervention: Primary series of NVX-CoV2373
Number of subjects: 1283
Study 37271721 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 107
Study 37271721 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 107
Study 37271818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin mass drug administration to humans and/or livestock
Number of subjects: 131818
Study 37271818 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 131818
Study 37271980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Polyposis Symptom Diary (NPSD)
Number of subjects: 518
Study 37271980 — intervention group
Group type: COMPARATOR
Intervention: 22-item Sino-Nasal Outcome Test (SNOT-22)
Number of subjects: 518
Study 37272079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ari 2MRTU 960
Number of subjects: 81
Study 37272079 — intervention group
Group type: COMPARATOR
Intervention: AOM 400
Number of subjects: 81
Study 37272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI (DCE-MRI + DW-MRI)
Number of subjects: 1678
Study 37272245 — intervention group
Group type: COMPARATOR
Intervention: DCE-MRI
Number of subjects: 1678
Study 37272375 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 40
Study 37272375 — intervention group
Group type: COMPARATOR
Intervention: Guselkumab 100 mg
Number of subjects: 40
Study 37272479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (LFD) combined with gluten-free diet (GFD)
Number of subjects: 0
Study 37272479 — intervention group
Group type: COMPARATOR
Intervention: Gluten-free diet (GFD)
Number of subjects: 0
Study 37272512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Number of subjects: 419
Study 37272512 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 419
Study 37272513 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg) plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) for up to 13 cycles.
Number of subjects: 797
Study 37272513 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and placebo for up to 13 cycles.
Number of subjects: 797
Study 37272521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg) subcutaneously once every 2 weeks
Number of subjects: 939
Study 37272521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study 37272527 — intervention group
Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel)
Number of subjects: 359
Study 37272527 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 359
Study 37272534 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 1128
Study 37272534 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 1128
Study 37272540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day for five days at months 0 and 12
Number of subjects: 1713
Study 37272540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg/day for three days at months 12 and 24
Number of subjects: 1713
Study 37272535 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 682
Study 37272535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study 37272947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 135
Study 37272947 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 135
Study 37272981 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Moral Case Deliberation (MCD)
Number of subjects: 435
Study 37272981 — intervention group
Group type: COMPARATOR
Intervention: No Structural MCD
Number of subjects: 435
Study 37273224 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 0.2-0.6 mg/h
Number of subjects: 141
Study 37273224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 37273273 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted group psychotherapy (including horses, rabbits, chickens, goats, and a dog)
Number of subjects: 3
Study 37273420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralasertib monotherapy 160 mg BID continuously
Number of subjects: 11
Study 37273420 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg BID followed by ceralasertib 160 mg BID 1 week on/3 weeks off
Number of subjects: 11
Study 37273449 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral risedronate for six months
Number of subjects: 24
Study 37273449 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for six months
Number of subjects: 24
Study 37273518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-free direct solitary cholangioscopy (DSC)
Number of subjects: 47
Study 37273518 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopic retrograde cholangiography (ERC)
Number of subjects: 47
Study 37273658 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based physical activity programming
Number of subjects: 0
Study 37273658 — intervention group
Group type: COMPARATOR
Intervention: Wellness counseling
Number of subjects: 0
Study 37273703 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Patient Program Catalonia™ (EPPC-MS)
Number of subjects: 144
Study 37273933 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week transdiagnostic stand-alone internet-based CBT intervention for assertiveness
Number of subjects: 0
Study 37273933 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37273934 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth ecosystem of stepped and personalized psychosocial care for 9 months
Number of subjects: 76
Study 37273934 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 37273942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulotaront (25, 50, or 75 mg/d)
Number of subjects: 38
Study 37273942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 37275501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt Liz (75% sodium and 25% potassium)
Number of subjects: 60
Study 37275501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt Liz
Number of subjects: 60
Study 37275501 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational entertainment activities
Number of subjects: 60
Study 37275631 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of standardized complementary food (10-12 weeks corrected for gestational age)
Number of subjects: 177
Study 37275631 — intervention group
Group type: COMPARATOR
Intervention: Late introduction of standardized complementary food (16-18 weeks corrected for gestational age)
Number of subjects: 177
Study 37275659 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in a private nursing home
Number of subjects: 78
Study 37275659 — intervention group
Group type: EXPERIMENTAL
Intervention: Having suffered a stroke
Number of subjects: 78
Study 37275884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus PD-1 blockade
Number of subjects: 0
Study 37275884 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 0
Study 37275927 — intervention group
Group type: EXPERIMENTAL
Intervention: Level I axillary dissection
Number of subjects: 61
Study 37275927 — intervention group
Group type: EXPERIMENTAL
Intervention: Level II axillary dissection
Number of subjects: 61
Study 37275956 — intervention group
Group type: EXPERIMENTAL
Intervention: Argan spinosa oil
Number of subjects: 140
Study 37275956 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone ointment
Number of subjects: 140
Study 37275963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy (ET)
Number of subjects: 0
Study 37275963 — intervention group
Group type: COMPARATOR
Intervention: Ribociclib (600-mg/day)
Number of subjects: 0
Study 37275983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients with higher hospitalization times
Number of subjects: 520
Study 37275983 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients with more hospitalization times
Number of subjects: 520
Study 37275983 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of depressive episode and functional rehabilitation
Number of subjects: 520
Study 37275983 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide times
Number of subjects: 520
Study 37276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Kool Kit (KK)
Number of subjects: 8
Study 37276032 — intervention group
Group type: COMPARATOR
Intervention: Arctic Sun with adhesive ArcticGel pads (AS)
Number of subjects: 8
Study 37276032 — intervention group
Group type: COMPARATOR
Intervention: Blanketrol III with two nonadhesive Maxi-Therm Lite blankets (BL)
Number of subjects: 8
Study 37276032 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanketrol III with nonadhesive Kool Kit (KK)
Number of subjects: 8
Study 37276053 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin in triheptanoin-naïve cohort
Number of subjects: 94
Study 37276053 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin in CL201 rollover cohort
Number of subjects: 94
Study 37276053 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin in IST/EAP cohort
Number of subjects: 94
Study 37276067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks (Cohort 3)
Number of subjects: 77